Browsing Tag
Argent BioPharma
2 posts
Argent BioPharma (ASX: RGT) acquires AusCann assets in $15m deal — can it unlock U.S. listing potential?
Argent BioPharma acquires AusCann assets in a $15M deal to expand its clinical pipeline, strengthen EU infrastructure, and advance toward a U.S. listing.
Why Argent BioPharma is leaving the London Stock Exchange—and what it means for investors
Argent BioPharma, a biopharmaceutical company specializing in innovative drug discovery, has announced its decision to delist from the…